Humana Inc. (HUM) EBITDA Margin: 2.24%
Is Humana Inc.’s EBITDA margin high or low?
Humana Inc.'s EBITDA margin of 2.24% is 51% below its 5-year average of 4.53%, near the low end of its 5-year range (2.24%–7.22%).
The EBITDA margin for Humana Inc. (HUM) is 2.24% as of Wednesday, June 10, 2026. It is below its 12-month average by 10.40% (2.50%).
HUM EBITDA Margin Chart
HUM Average EBITDA Margin Chart
HUM Current vs Average EBITDA Margin Chart
HUM EBITDA Margin Metrics
EBITDA MARGIN
2.24%
EBITDA MARGIN AVG TTM
2.50%
EBITDA MARGIN AVG 3Y
3.66%
EBITDA MARGIN AVG 5Y
4.53%
EBITDA MARGIN AVG 10Y
3.32%
EBITDA MARGIN AVG 15Y
2.32%
EBITDA MARGIN AVG 20Y
1.94%
CURRENT VS TTM AVG
-10.40%
CURRENT VS 3Y AVG
-38.71%
CURRENT VS 5Y AVG
-50.53%
CURRENT VS 10Y AVG
-32.47%
CURRENT VS 15Y AVG
-3.37%
CURRENT VS 20Y AVG
+15.75%
HUM Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humana Inc. (HUM) | — | 2.24% | 2.50% | 3.66% | 4.53% |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 34.13% | 33.43% | 32.56% | 31.99% |
| Agilent Technologies, Inc. (A) | $38.26B | 26.41% | 27.60% | 26.98% | 26.47% |
| Zoetis Inc. (ZTS) | $34.20B | 42.98% | 42.41% | 42.38% | 41.76% |
| Centene Corporation (CNC) | $31.94B | -2.64% | 0.58% | 1.90% | 2.49% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 21.24% | 21.82% | 21.39% | 20.63% |
| DexCom, Inc. (DXCM) | $29.24B | 24.96% | 24.20% | 23.29% | 21.36% |
| Biogen Inc. (BIIB) | $29.00B | 31.60% | 31.28% | 30.38% | 32.54% |
| Veeva Systems Inc. (VEEV) | $27.37B | 28.68% | 27.64% | 24.37% | 25.68% |
| Regeneron Pharmaceuticals, Inc. (REGN) | $62.59B | 40.57% | 39.01% | 39.25% | 44.24% |
Margin Comparison
Gross Margin
14.0%
EBITDA Margin
2.2%
Operating Margin
1.0%
Net Margin
0.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Humana Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Humana Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Humana Inc. (HUM)?
- The EBITDA margin for HUM stock is 2.24%.
- Is Humana Inc.'s EBITDA margin high or low?
- Humana Inc.'s EBITDA margin of 2.24% is 51% below its 5-year average of 4.53%, near the low end of its 5-year range (2.24%–7.22%).
- What is the TTM average EBITDA margin for Humana Inc. (HUM)?
- The TTM average EBITDA margin for HUM stock is 2.50%.
- What is the 3Y average EBITDA margin for Humana Inc. (HUM)?
- The 3Y average EBITDA margin for HUM stock is 3.66%.
- What is the 5Y average EBITDA margin for Humana Inc. (HUM)?
- The 5Y average EBITDA margin for HUM stock is 4.53%.
- What is the 10Y average EBITDA margin for Humana Inc. (HUM)?
- The 10Y average EBITDA margin for HUM stock is 3.32%.
- What is the 15Y average EBITDA margin for Humana Inc. (HUM)?
- The 15Y average EBITDA margin for HUM stock is 2.32%.
- What is the 20Y average EBITDA margin for Humana Inc. (HUM)?
- The 20Y average EBITDA margin for HUM stock is 1.94%.
Humana Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 2.24% |
| 2024-12-31 | 2.76% |
| 2023-12-31 | 4.44% |
| 2022-12-31 | 5.18% |
| 2021-12-31 | 5.33% |
| 2020-12-31 | 7.22% |
| 2019-12-31 | 6.60% |
| 2018-12-31 | 4.96% |
| 2017-12-31 | -1.74% |
| 2016-12-31 | 0.00% |
| 2015-12-31 | -0.50% |
| 2014-12-31 | 0.00% |
| 2013-12-31 | 0.00% |
| 2012-12-31 | 0.12% |
| 2011-12-31 | 0.00% |
| 2010-12-31 | 0.48% |
| 2009-12-31 | 0.00% |
| 2008-12-31 | 0.35% |
| 2007-12-31 | 0.00% |
| 2006-12-31 | 0.00% |
| 2005-12-31 | 3.20% |
| 2004-12-31 | 4.17% |
| 2003-12-31 | 3.93% |
| 2002-12-31 | 3.03% |
| 2001-12-31 | 3.72% |
| 2000-12-31 | 2.80% |
| 1999-12-31 | -2.39% |
| 1998-12-31 | 3.83% |
| 1997-12-31 | 1.59% |
| 1996-12-31 | 1.61% |
Related Metrics
About Humana Inc.
Humana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services. The firm provides a wide array of medical and supplementary insurance plans directly to individual consumers. Furthermore, Humana collaborates with government entities; it holds a contract with the Centers for Medicare and Medicaid Services (CMS) to manage the Limited Income Newly Eligible Transition (LI NET) prescription drug program. The company also secures agreements with numerous states to deliver Medicaid, dual-eligible, and long-term care support benefits. For employer groups and individuals, Humana furnishes fully insured commercial medical and specialized health coverage, which encompasses dental, vision, and other ancillary health benefits. They additionally offer administrative services only (ASO) solutions and extend support to military personnel through contracts like the TRICARE T2017 East Region. Beyond insurance products, the company delivers comprehensive healthcare services directly. These include pharmacy management, provider network services, and a suite of home-based solutions such as home health care, serving both its own health plan enrollees and external clients. By the close of 2021 (December 31), Humana's reach extended to approximately 17 million individuals enrolled in its medical benefit plans and an additional 5 million utilizing its specialized product offerings. Established in 1961, Humana Inc. maintains its corporate headquarters in Louisville, Kentucky.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- CEO
- James A. Rechtin